ANTONIO RAFAEL
ANTELA LOPEZ
PhD hired professor
Hospital Universitari Germans Trias i Pujol
Barcelona, EspañaPublications in collaboration with researchers from Hospital Universitari Germans Trias i Pujol (40)
2024
-
Acceptability of Long-Acting Injectable Antiretroviral Treatment for HIV Management: Perspectives of Patients and Physicians in Spain
AIDS Patient Care and STDs, Vol. 38, Núm. 7, pp. 305-314
2023
-
Effectiveness and safety of integrase strand transfer inhibitors in Spain: a prospective real-world study
Frontiers in Cellular and Infection Microbiology, Vol. 13
2022
-
Discovering HIV related information by means of association rules and machine learning
Scientific Reports, Vol. 12, Núm. 1
-
Patient-Reported Outcomes (PROs) in HIV Infection: Points to Consider and Challenges
Infectious Diseases and Therapy, Vol. 11, Núm. 5, pp. 2017-2033
-
Predictors of low-level HIV viraemia and virological failure in the era of integrase inhibitors: A Spanish nationwide cohort
HIV Medicine, Vol. 23, Núm. 8, pp. 825-836
2021
-
Redefining therapeutic success in HIV patients: An expert view
Journal of Antimicrobial Chemotherapy, Vol. 76, Núm. 10, pp. 2501-2518
2020
-
Primary resistance to integrase strand transfer inhibitors in Spain using ultrasensitive HIV-1 genotyping
Journal of Antimicrobial Chemotherapy, Vol. 75, Núm. 12, pp. 3517-3524
2019
2018
-
Impact of co-infection by hepatitis C virus on immunological and virological response to antiretroviral therapy in HIV-positive patients
Medicine (United States), Vol. 97, Núm. 38
-
Low-level viremia is associated with clinical progression in HIV-infected patients receiving antiretroviral treatment
Journal of Acquired Immune Deficiency Syndromes, Vol. 78, Núm. 3, pp. 329-337
-
Real world patient-reported outcomes in HIV-infected adults switching to EVIPLERA®, because of a previous intolerance to cART. PRO-STR study
Current HIV Research, Vol. 16, Núm. 6, pp. 425-435
2017
-
Executive summary: Pre-exposure prophylaxis for prevention of HIV infection in adults in Spain: July 2016
Enfermedades Infecciosas y Microbiologia Clinica, Vol. 35, Núm. 6, pp. 377-383
-
Prediction of long-term outcomes of HIV-infected patients developing non-AIDS events using a multistate approach
PLoS ONE, Vol. 12, Núm. 9
-
Simplification to dual therapy (atazanavir/ritonavir1lamivudine) versus standard triple therapy [atazanavir/ritonavir1two nucleos(t)ides] in virologically stable patients on antiretroviral therapy: 96 week results from an open-label, non-inferiority, randomized clinical trial (SALT study)
Journal of Antimicrobial Chemotherapy, Vol. 72, Núm. 1, pp. 246-253
2016
-
Impact of late presentation of HIV infection on short-, mid- and long-term mortality and causes of death in a multicenter national cohort: 2004-2013
Journal of Infection, Vol. 72, Núm. 5, pp. 587-596
-
Sexual activity without condoms and risk of HIV transmission in serodifferent couples when the HIV-positive partner is using suppressive antiretroviral therapy
JAMA - Journal of the American Medical Association, Vol. 316, Núm. 2, pp. 171-181
-
Withdrawing inactive NRTIs in HIV-1 subjects with suppressed viraemia: A randomized trial
Journal of Antimicrobial Chemotherapy, Vol. 71, Núm. 5, pp. 1346-1351
2015
-
Dual treatment with atazanavir-ritonavir plus lamivudine versus triple treatment with atazanavir-ritonavir plus two nucleos(t)ides in virologically stable patients with HIV-1 (SALT): 48 week results from a randomised, open-label, non-inferiority trial
The Lancet Infectious Diseases, Vol. 15, Núm. 7, pp. 775-784
-
Outcome of neuropsychiatric symptoms related to an antiretroviral drug following its substitution by nevirapine: The RELAX study
HIV Medicine, Vol. 16, Núm. 10, pp. 628-634
-
Virological failure to raltegravir in Spain: Incidence, prevalence and clinical consequences
Journal of Antimicrobial Chemotherapy, Vol. 70, Núm. 11, pp. 3087-3095